Literature DB >> 12597888

A bicistronic expression system for bacterial production of authentic human interleukin-18.

Robert B Kirkpatrick1, Patrick J McDevitt, Rosalie E Matico, Silas Nwagwu, Stephen H Trulli, Joyce Mao, Dwight D Moore, Adam F Yorke, Megan M McLaughlin, Kristin A Knecht, Louis C Elefante, Amy S Calamari, Jim A Fornwald, John J Trill, Zdenka L Jonak, James Kane, Pramathesh S Patel, Ganesh M Sathe, Allan R Shatzman, Peter M Tapley, Kyung O Johanson.   

Abstract

Interleukin-18 (IL-18) is activated and released from immune effector cells to stimulate acquired and innate immune responses involving T and natural killer (NK) cells. The release of IL-18 from mammalian cells is linked to its proteolytic activation by caspases including interleukin 1 converting enzyme (ICE). The absence of a signal peptide sequence and the requirement for coupled activation and cellular release have presented challenges for the large-scale recombinant production of IL-18. In this study, we have explored methods for the direct production of authentic human IL-18 toward the development of a large-scale production system. Expression of mature IL-18 directly in Escherichia coli with a methionine initiating codon leads to the production of MetIL-18 that is dramatically less potent in bioassays than IL-18 produced as a pro-peptide and activated in vitro. To produce an authentic IL-18, we have devised a bicistronic expression system for the coupled transcription and translation of ProIL-18 with caspase-1 (ICE) or caspase-4 (ICE-rel II, TX, ICH-2). Mature IL-18 with an authentic N-terminus was produced and has a biological activity and potency comparable to that of in vitro processed mature IL-18. Optimization of this system for the maximal production yields can be accomplished by modulating the temperature, to affect the rate of caspase activation and to favor the accumulation of ProIL-18, prior to its proteolytic processing by activated caspase. The effect of temperature is particularly profound for the caspase-4 co-expression process, enabling optimized production levels of over 150 mg/L in shake flasks at 25 degrees C. An alternative bicistronic expression design utilizing a precise ubiquitin IL-18 fusion, processed by co-expressed ubiquitinase, was also successfully used to generate fully active IL-18, thereby demonstrating that the pro-sequence of IL-18 is not required for recombinant IL-18 production. Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12597888     DOI: 10.1016/s1046-5928(02)00606-x

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  Ligation independent cloning vectors for expression of SUMO fusions.

Authors:  Stephen D Weeks; Mark Drinker; Patrick J Loll
Journal:  Protein Expr Purif       Date:  2006-12-13       Impact factor: 1.650

3.  Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.

Authors:  Richard G Carroll; Carmine Carpenito; Xiaochuan Shan; Gwenn Danet-Desnoyers; Ronghua Liu; Shuguang Jiang; Steven M Albelda; Tatiana Golovina; George Coukos; James L Riley; Zdenka L Jonak; Carl H June
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

4.  An innate interaction between IL-18 and the propeptide that inactivates its precursor form.

Authors:  Naotaka Tsutsumi; Ayumi Yokota; Takeshi Kimura; Zenichiro Kato; Toshiyuki Fukao; Masahiro Shirakawa; Hidenori Ohnishi; Hidehito Tochio
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

Review 5.  Seamless cloning and gene fusion.

Authors:  Quinn Lu
Journal:  Trends Biotechnol       Date:  2005-04       Impact factor: 19.536

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.